Solifenacin for overactive bladder: A systematic review and meta-analysis

International Urogynecology Journal

Volumn 23, Issue 8, 2012, Pages 983-991

  Luo, Deyi ^a   Liu, Liangren ^a   Han, Ping ^a   Wei, Qiang ^a   Shen, Hong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Overactive bladder; Solifenacin; Tolterodine

Indexed keywords

PLACEBO; SOLIFENACIN; TOLTERODINE;

BLURRED VISION; CONSTIPATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MICTURITION; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

EID: 84865120933     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-011-1641-7     Document Type: Review

References (31)

1. Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society. Urology 61(1):37-49 (Pubitemid 36151708)
2. Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87(9):760-766 (Pubitemid 34204313)
3. Chapple CR (2007) Advancing the management of overactive bladder: new data, new directions. Eur Urol Suppl 6:1-3 (Pubitemid 44821936)
4. Reeves P, Irwin D, Kelleher C et al (2006) The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50:1050-1057 (Pubitemid 44486484)
5. Hampel C (2007) Long-term management of overactive bladder with antimuscarinic agents. Eur Urol Suppl 6:432-437 (Pubitemid 46199339)
6. Chapple CR, Martinez-Garcia R, Selvaggi L et al (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48: 464-470 (Pubitemid 41188406)
7. Choo MS, Lee JB, Kim YH et al (2008) Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomized, prospective, double-blind, multicentre study. Int J Clin Pract 62(11):1675-1683
8. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12 (Pubitemid 26120810)
9. Cardozo L, Hessdörfer E, Milani R, SUNRISE Study Group et al (2008) Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, doubleblind, placebo-controlled, rising-dose trial. BJU Int 102(9): 1120-1127
10. Karram MM, Toglia MR, Serels SR et al (2009) Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, doubleblind, placebo-controlled trial. Urology 73(1):14-18
11. Toglia MR, Serels SR, Laramée C et al (2009) Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgrad Med 121(5):151-158
12. Toglia MR, Ostergard DR, Appell RA et al (2010) Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. Int Urogynecol J Pelvic Floor Dysfunct 21(7):847-854
13. Serels SR, Toglia MR, Forero-Schwanhaeuser S et al (2010) Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Curr Med Res Opin 26(10):2277-2285
14. Chapple CR, Fianu-Jonsson A, Indig M et al (2007) STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 52 (4):1195-1203 (Pubitemid 47337035)
15. Chapple CR, Rechberger T, Al-Shukri S et al (2004) YM-905 Study Group. Randomized, double-blind placebo- and tolterodinecontrolled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93 (3):303-310 (Pubitemid 38253574)
16. Ho CH, Chang TC, Lin HH et al (2010) Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc 109(10):702-708
17. Chapple CR, Araño P, Bosch JL et al (2004) Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 93(1):71-77 (Pubitemid 38112970)
18. Vardy MD, Mitcheson HD, Samuels TA et al (2009) Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. Int J Clin Pract 63(12): 1702-1714
19. Cardozo L, Lisec M, Millard R et al (2004) Randomized, doubleblind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172(5 Pt 1):1919-1924 (Pubitemid 39363090)
20. Michel MC, de la Rosette JJ (2005) Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int 96 (suppl 1):37-42 (Pubitemid 41224306)
21. Landis RJ, Kaplan S, Swift S et al (2004) Efficacy of antimuscarinic therapy for overactive bladder with varying degree of incontinence severity. J Urol 171:752-756 (Pubitemid 38090474)
22. Staskin DR, MacDiarmid SA (2006) Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med 119:24-28
23. Alhasso AA, McKinlay J, Patrick K et al (2006) Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 18(4):CD003193
24. Epstein BJ, Gums JG, Molina E (2006) Newer agents for the management of overactive bladder. Am Fam Physician 74: 2061-2068 (Pubitemid 44927019)
25. Chapple CR, Khullar V, Gabriel Z et al (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543-562
26. Eglen RM, Hedge SS, Watson N (1996) Muscarinic receptor subtypes and smooth function. Pharmacol Rev 48:531-565 (Pubitemid 27023820)
27. Haab F, Van Kerrebroeck P, Huang M, et al (2004) Solifenacin associated with high persistence on therapy in long-term overactive bladder extension study Third International consultation on Incontinence; June 26-28 (Monte Carlo): Monaco
28. Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(Suppl 5A):33-46
29. Ginsberg DA, Phillips SE, Wallace J et al (2007) Evaluating and managing constipation in the elderly. Urol Nurs 27:191-200
30. Rosenberg MT, Newman DK, Tallman CT et al (2007) Overactive bladder: recognition requires vigilance for symptoms. Cleve Clin J Med 74(Suppl 3):S21-S29
31. Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987-1006 (Pubitemid 47537675)